851398-76-0
851398-76-0
Chemical Structure
N6F11
- CAS No.: 851398-76-0
- Formula:C13H8Cl2N2OS
- Molecular Weight:311.19
InChIKey: KXALOVOFOCKYSD-UHFFFAOYSA-N
SMILES: ClC1=CC=C(C2=CC3=C(C(NC(CCl)=N3)=O)S2)C=C1
Biological Activity: N6F11 is a selective ferroptosis inducer, and can selectively induce ferroptosis by targeting TRIM25-mediated GPX4 degradation in cancer cells while sparing immune cells. N6F11 initiates HMGB1-dependent antitumor immunity mediated by CD8+ T cells[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
N6F11 | 98.08% | N6F11 is a selective ferroptosis inducer, and can selectively induce ferroptosis by targeting TRIM25-mediated GPX4 degradation in cancer cells while sparing immune cells. N6F11 initiates HMGB1-dependent antitumor immunity mediated by CD8+ T cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.70
HY-174393Gamhepathiopine -
Similarity Score 0.61
HY-155354Antimalarial agent 33 -
Similarity Score 0.60
HY-W472153β-Glucuronidase-IN-5 -
Similarity Score 0.60
HY-143431Cdc7-IN-17 -
Similarity Score 0.58
HY-133486GABAA receptor agent 1 -
Similarity Score 0.57
HY-162238OSM-S-106 -
Similarity Score 0.57
HY-143226DK1 -
Similarity Score 0.55
HY-W965550Apoptosis inducer 40 -
Similarity Score 0.55
HY-128153Thienopyridone -
Explore the MedChemAI to find more analogs
References
- [1]. Li J, et al. Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer. Sci Transl Med. 2023;15(720):eadg3049. [Content Brief]
- [2]. Liu J, et al. Cell type-specific induction of ferroptosis to boost antitumor immunity. Oncoimmunology. 2023 Nov 20;12(1):2282252. [Content Brief]
- [3]. Shi TM, et al. Ferroptosis-Based Therapeutic Strategies toward Precision Medicine for Cancer. J Med Chem. 2024 Feb 22;67(4):2238-2263. [Content Brief]
- [4]. Liu J, et al. Adverse effects of ferroptotic therapy: mechanisms and management. Trends Cancer. 2024 May;10(5):417-429. [Content Brief]
